The Efficacy of Solifenacin Succinate as Adjuvant Therapy for Urinary Tract Infection in Females
Information source: Dr Cipto Mangunkusumo General Hospital
ClinicalTrials.gov processed this data on August 23, 2015 Link to the current ClinicalTrials.gov record.
Condition(s) targeted: Urinary Tract Infection
Intervention: Levofloxacin (Drug); Solifenacin succinate (Drug); Placebo (for Solifenacin succinate) (Drug)
Phase: Phase 4
Status: Recruiting
Sponsored by: Dr Cipto Mangunkusumo General Hospital
Summary
The efficacy of Solifenacin Succinate 5 mg as adjuvant therapy and levofloxacin (500 mg)
for short-term treatment to reduce symptoms in patients with symptomatic non complicated
urinary tract infection in females.
Clinical Details
Official title: The Efficacy of Solifenacin Succinate as Adjuvant Therapy for Symptomatic Non-complicated Urinary Tract Infection in Females
Study design: Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment
Primary outcome: Number of participants with storage symptoms
Eligibility
Minimum age: 18 Years.
Maximum age: 65 Years.
Gender(s): Female.
Criteria:
Inclusion Criteria:
- females (18-65 years old)
- dysuria in symptomatic non complicated urinary tract infection
Exclusion Criteria:
- Pediatric Patients (< 18 years old)
- geriatric Patients (> 65 years old)
- pregnant Patients
- Patients with complicated urinary tract infection
- sexually transmitted infections
- Patients with pathological abnormalities in the urinary bladder, including stone/mass
- Catheter-mounted
- Neurological diseases/disorders
- patients with allergy/hypersensitivity with Levofloxacin/Solifenacin
Locations and Contacts
Cipto Mangunkusumo Hospital, Jakarta 10430, Indonesia; Recruiting Harrina Erlianti Rahardjo, Phone: +62 816-825-226, Email: harrinaerlianti@yahoo.com
Additional Information
Starting date: April 2013
Last updated: March 19, 2014
|